Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2020

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation

Résumé

Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, there is limited data about the optimal duration of treatment and the risk of relapse after anti-PD1 discontinuation. We have previously reported the outcome of 11 patients with R/R HL who discontinued anti-PD1 therapy after achieving a complete response (CR) upon nivolumab1 . These patients experienced favorable outcome as only 2 of them had relapsed after a median follow-up of 21.2 months from discontinuation. Despite the low relapse rate observed in that study, physicians may be worried about the possibility to further rescue these heavily pre-treated patients in case of relapse after anti-PD1 discontinuation. Notably, it is still unknown whether these patients will remain sensitive to a 2nd course of anti-PD1.
Fichier principal
Vignette du fichier
Manson et al-2020-Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who.pdf (1.71 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02485796 , version 1 (25-03-2020)

Identifiants

Citer

Guillaume Manson, Pauline Brice, Charles Herbaux, Kamal Bouabdallah, Chloé Antier, et al.. Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation. Haematologica, 2020, 105 (11), pp.2664-2666. ⟨10.3324/haematol.2019.242529⟩. ⟨hal-02485796⟩
122 Consultations
54 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More